Home » Healthcare » At-Home Cancer Testing Market

At Home Cancer Testing Market By Cancer Type (Colon, Breast, Prostate, Blood, Bladder, Others); By Sample Type (Blood, Urine, Cell, Stool, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: At-Home Cancer Testing Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-09
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: At-Home Cancer Testing Market

Summary
Table Of Content
Request Sample

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
At-Home Cancer Testing Market Size 2024	USD 8,047.53 million
At-Home Cancer Testing Market, CAGR	4.33%
At-Home Cancer Testing Market Size 2032	USD 11,576.07 million

Market Overview

The At-Home Cancer Testing Market size was valued at USD 6,037.48 million in 2018, reached USD 8,047.53 million in 2024, and is anticipated to reach USD 11,576.07 million by 2032, growing at a CAGR of 4.33% during the forecast period.

The At-Home Cancer Testing market is highly competitive, with key players such as Exact Sciences Corporation, Guardant Health, Grail, Inc., Everlywell, Natera, Illumina Inc., Cisco, Myriad Genetics Inc., NeoGenomics Laboratories, and Freenome Holdings Inc. driving innovation and market expansion. These companies focus on developing advanced, user-friendly diagnostic solutions, leveraging technologies like liquid biopsy, genetic screening, and direct-to-consumer platforms. North America leads the market, accounting for approximately 32.1% of the global share in 2024, driven by high consumer awareness, advanced healthcare infrastructure, and early adoption of home-based diagnostics. Asia Pacific follows closely with significant growth potential, supported by rising cancer prevalence, increasing healthcare investments, and expanding digital health ecosystems.

Market Insights

The At-Home Cancer Testing market was valued at USD 8,047.53 million in 2024 and is projected to reach USD 11,576.07 million by 2032, growing at a CAGR of 4.33% during the forecast period.
Rising demand for early cancer detection, increasing awareness of preventive healthcare, and growing preference for home-based testing solutions are key drivers supporting market growth globally.
The market is witnessing trends such as the rapid expansion of online pharmacies, increasing adoption of direct-to-consumer models, and integration of digital health platforms and telemedicine for seamless patient support.
Competitive dynamics are shaped by key players like Exact Sciences Corporation, Guardant Health, Grail, Inc., Everlywell, and Natera, focusing on technological advancements, strategic partnerships, and product portfolio expansion to strengthen their market positions.
North America leads with a 32.1% share in 2024, followed by Asia Pacific with 41.5%; the blood sample segment holds the largest market share due to its ease of use and higher accuracy.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segmentation Analysis:

By Cancer Type

In the At-Home Cancer Testing market, the colon cancer segment holds the largest market share, driven by the rising prevalence of colorectal cancer and the increasing demand for early detection methods. Colon cancer tests are widely accepted due to their non-invasive nature and their ability to detect cancer at an early stage, significantly improving survival rates. The convenience of home-based stool DNA testing kits and growing awareness of routine screening among the aging population further support the segment’s dominance. Continuous advancements in test accuracy and accessibility also contribute to its market leadership.

For instance, Exact Sciences Corporation’s Cologuard test, a non-invasive stool DNA test, has been used in over 10 million completed screenings in the United States as of 2023, demonstrating widespread adoption and clinical impact.

By Sample Type

The blood sample segment dominates the At-Home Cancer Testing market, accounting for the highest market share owing to its ease of collection, high patient compliance, and increasing preference for minimally invasive procedures. Blood-based tests, particularly liquid biopsies, offer efficient detection of multiple cancer types with high accuracy and faster turnaround times. Technological advancements in biomarker identification and the growing availability of blood-based home testing kits are further propelling this segment’s growth. Additionally, healthcare providers and patients increasingly prefer blood samples for their reliability in monitoring disease progression and treatment effectiveness.

For instance, Guardant Health’s Guardant360 liquid biopsy has been utilized in more than 400,000 clinical tests worldwide as of 2023, underscoring the growing preference for blood-based diagnostics in oncology.

By Distribution Channel

Online pharmacies lead the distribution channels in the At-Home Cancer Testing market, capturing the largest market share due to their convenience, wide product availability, and discrete purchasing options. The rapid expansion of e-commerce platforms and improved access to home testing kits have significantly boosted online sales. Additionally, rising consumer trust in digital health solutions and the availability of direct-to-consumer cancer testing kits have further accelerated segment growth. The ease of home delivery and the increasing preference for privacy and self-management in health monitoring are key drivers sustaining the dominance of online pharmacies.

Market Overview

Rising Demand for Early Cancer Detection

The increasing focus on early diagnosis is a major growth driver in the At-Home Cancer Testing market. Early detection significantly improves survival rates and treatment outcomes, encouraging individuals to adopt convenient home-based testing solutions. Growing public awareness, supported by government and non-profit initiatives, is further promoting preventive healthcare practices. The shift towards proactive health monitoring, combined with the aging global population prone to cancer risks, is accelerating the demand for accessible, timely, and user-friendly at-home cancer detection kits.

For instance, Grail, Inc.’s Galleri multi-cancer early detection test has screened over 60,000 patients as part of its PATHFINDER and REFLECTION clinical programs by 2023, reflecting the strong consumer and clinical interest in early cancer detection.

Advancements in Testing Technologies

Technological advancements, particularly in liquid biopsy, biomarker identification, and genetic testing, are driving the At-Home Cancer Testing market forward. Innovations have improved the accuracy, sensitivity, and reliability of home testing kits, making them competitive with traditional diagnostic methods. These advancements allow for multi-cancer detection from a single sample and enable faster processing times. The integration of digital platforms and AI for result interpretation further enhances the consumer experience, strengthening trust and adoption rates across diverse population groups.

For instance, Illumina’s NovaSeq 6000 platform can sequence up to 48 whole human genomes in under two days, enabling high-throughput genomic analysis that supports the rapid development of at-home genetic cancer screening solutions.

Growing Preference for Home-Based Healthcare Solutions

The preference for home-based healthcare has surged, especially post-pandemic, fostering significant growth in the At-Home Cancer Testing market. Consumers increasingly value privacy, convenience, and reduced exposure to clinical settings. This trend is amplified by busy lifestyles, rising healthcare costs, and improved access to over-the-counter and online testing kits. Direct-to-consumer models empower individuals to take charge of their health, which is particularly attractive to those seeking discreet cancer screening options without the need for extensive hospital visits or consultations.

Key Trends & Opportunities

Expansion of Online Distribution Channels

The rapid growth of online pharmacies and e-commerce platforms presents a key opportunity in the At-Home Cancer Testing market. Online availability enhances accessibility and supports discreet purchasing, encouraging consumer adoption. Partnerships between test manufacturers and digital health platforms further streamline product distribution and awareness. With the increasing use of mobile apps and telehealth services, online channels offer an efficient pathway for consumers to order, use, and receive guidance on at-home cancer testing kits, boosting market penetration.

For instance, Everlywell has distributed over 2 million at-home health test kits, including cancer screening products, through its online platform as of 2023, making it one of the largest direct-to-consumer testing providers in the U.S.

Integration of Telehealth and Digital Platforms

The integration of telehealth services and digital reporting platforms is transforming the At-Home Cancer Testing market. Consumers now expect seamless digital experiences, including online consultations, virtual result discussions, and real-time guidance. This trend not only improves patient engagement but also enhances test accuracy through professional oversight. Companies leveraging telemedicine can build trust and offer added value, providing a comprehensive at-home diagnostic ecosystem that appeals to a tech-savvy consumer base and expands market growth opportunities.

For instance, Myriad Genetics launched its digital platform, Myriad Complete, in 2023, which has processed over 100,000 virtual consultations, providing patients with remote access to genetic counselors and test interpretation services.

Key Challenges

Regulatory and Quality Assurance Complexities

The At-Home Cancer Testing market faces stringent regulatory hurdles related to product approvals, accuracy standards, and consumer safety. Ensuring test reliability outside clinical settings presents a major challenge, as home users may not always follow procedures correctly. Regulatory bodies require extensive validation and compliance, often leading to delayed market entry. Continuous monitoring, post-market surveillance, and ensuring consistency in home-use environments remain critical concerns for manufacturers aiming to sustain credibility and consumer trust.

Limited Awareness and Accessibility in Developing Regions

Despite growing global demand, limited awareness and accessibility in low- and middle-income countries pose significant challenges. Factors such as lack of consumer education, low digital penetration, and insufficient distribution networks restrict market growth in these regions. Additionally, cultural stigma surrounding cancer and home diagnostics can hinder adoption. Companies must invest in targeted awareness campaigns and affordable product offerings to overcome these barriers and unlock untapped potential in emerging markets.

Risk of Misinterpretation and False Results

One of the key challenges in the At-Home Cancer Testing market is the risk of users misinterpreting results, leading to false reassurance or unnecessary anxiety. Unlike clinical settings where professionals guide the process, home testing relies heavily on user accuracy and understanding. False positives or negatives can result in either overlooked treatment or undue psychological stress. Addressing this issue requires robust user instructions, follow-up telehealth support, and the development of highly intuitive testing kits to minimize user error.

Regional Analysis

North America

In 2018, North America accounted for USD 1,939.42 million in the At-Home Cancer Testing market, holding a market share of approximately 32.1%. The region’s market is projected to reach USD 2,548.61 million in 2024 and is anticipated to grow to USD 3,679.98 million by 2032, registering a CAGR of 4.4% during the forecast period. North America maintains its dominance due to advanced healthcare infrastructure, high consumer awareness, and early adoption of home-based health technologies. The increasing prevalence of cancer and the expansion of direct-to-consumer testing services further support sustained regional growth.

Europe

Europe held a market value of USD 1,131.73 million in 2018, contributing around 18.7% to the global At-Home Cancer Testing market. By 2024, the market is expected to reach USD 1,426.21 million and is projected to grow to USD 1,866.33 million by 2032, with a CAGR of 3.1%. The region’s growth is driven by rising cancer incidence, growing preference for home-based screening, and supportive government initiatives promoting early detection. However, regulatory complexities and cost concerns somewhat moderate growth, despite the increasing availability of advanced home testing kits across key European countries.

Asia Pacific

Asia Pacific dominated the global market in 2018, valued at USD 2,405.63 million and commanding the largest market share of approximately 39.8%. The market is forecasted to reach USD 3,336.39 million in 2024 and USD 5,119.23 million by 2032, expanding at the fastest CAGR of 5.2%. Rapid urbanization, increasing healthcare awareness, and a growing middle-class population are key drivers of regional growth. Additionally, the rising burden of cancer and growing digital health adoption across countries such as China, India, and Japan significantly contribute to the strong market potential in this region.

Latin America

Latin America accounted for USD 279.78 million in 2018, representing about 4.6% of the global At-Home Cancer Testing market. By 2024, the market is expected to reach USD 368.20 million and is projected to grow to USD 467.59 million by 2032, at a CAGR of 2.7%. The region’s growth is supported by improving healthcare access, gradual adoption of home testing solutions, and increasing cancer awareness initiatives. However, limited consumer awareness in rural areas and affordability concerns may restrict faster market penetration compared to more developed regions.

Middle East

The At-Home Cancer Testing market in the Middle East was valued at USD 171.77 million in 2018, capturing approximately 2.8% of the global market share. The market is estimated to grow to USD 209.59 million in 2024 and reach USD 255.18 million by 2032, registering a CAGR of 2.2%. Growing investments in healthcare infrastructure and the gradual adoption of advanced diagnostic technologies are driving market expansion. Nevertheless, the uptake of home-based cancer testing remains limited due to lower awareness and cultural hesitancy toward self-diagnosis, posing moderate growth challenges.

Africa

Africa contributed USD 109.16 million to the At-Home Cancer Testing market in 2018, holding the smallest market share of approximately 1.8%. The market is forecasted to reach USD 158.54 million in 2024 and is anticipated to grow to USD 187.78 million by 2032, at a modest CAGR of 1.8%. While awareness about cancer and home diagnostic options is gradually increasing, significant barriers such as limited healthcare infrastructure, low affordability, and insufficient distribution channels hinder widespread adoption. The region offers potential for growth, but requires substantial investment in awareness programs and healthcare accessibility.

Market Segmentations:

By Cancer Type

Colon
Breast
Prostate
Blood
Bladder
Others

By Sample Type

Blood
Urine
Cell
Stool
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Geography:

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Competitive Landscape

The At-Home Cancer Testing market is characterized by the presence of several key players actively engaged in developing innovative, user-friendly diagnostic solutions. Companies such as Exact Sciences Corporation, Guardant Health, Grail, Inc., Everlywell, and Natera are focusing on expanding their product portfolios to cover a wider range of cancer types, including colon, breast, and prostate cancers. Market leaders are leveraging technological advancements like liquid biopsy, genetic screening, and AI-driven diagnostics to improve accuracy and convenience. Strategic collaborations, acquisitions, and partnerships are common approaches to enhance distribution networks and accelerate market penetration. Additionally, players like Illumina Inc. and Myriad Genetics Inc. are investing significantly in research and development to maintain competitive advantage. The growing trend of direct-to-consumer models and the expansion of online sales channels further intensify competition. Continuous product innovation and regulatory approvals remain crucial factors shaping the competitive dynamics in this rapidly evolving market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Exact Sciences Corporation
Guardant Health
Grail, Inc.
Everlywell
Natera
Illumina Inc.
Cisco
Myriad Genetics Inc.
NeoGenomics Laboratories
Freenome Holdings Inc.

Recent Developments

In June 2025, GRAIL announced positive preliminary results from the PATHFINDER 2 study of its Galleri multi-cancer early detection (MCED) blood test. The study showed improved cancer detection and predictive accuracy compared to previous studies. GRAIL is preparing to submit these results to the FDA to seek full marketing approval for the Galleri test.
In June 2025, Everlywell announced a collaboration with Grail to offer the Galleri MCED test via prescription through Everlywell’s online platform, expanding at-home access to this multi-cancer blood test.
In May 2025, Guardant Health launched the Guardant Hereditary Cancer test, a blood-based germline panel designed to identify inherited genetic variants linked to cancer risk. This test analyzes 82 genes across more than 12 tumor types, aiding in personalized cancer screening and prevention strategies. It helps identify individuals with an elevated risk for certain cancers, enabling tailored screening and preventative measures.
In April 2025, Exact Sciences was indeed a prominent player in the multi-cancer early detection (MCED) market, specifically focusing on blood-based minimal residual disease (MRD) tests. They were actively developing these tests and were planning to launch their own competitor, Oncodetect™, in the second quarter of 2025.

Market Concentration & Characteristics

The At-Home Cancer Testing Market demonstrates a moderately concentrated structure with a mix of established diagnostic companies and emerging technology-driven players. It features strong competition among key participants such as Exact Sciences Corporation, Guardant Health, Grail, Inc., Everlywell, and Natera, each focusing on expanding their product portfolios and improving test accuracy. The market shows high barriers to entry due to strict regulatory standards and the need for proven clinical efficacy. It benefits from the growing consumer shift toward personalized healthcare and self-monitoring solutions, which continue to support steady demand. It relies heavily on technological innovation, with companies introducing user-friendly kits, digital reporting, and telehealth integration to strengthen market presence. The market is shaped by the rising importance of convenience and privacy in cancer screening, which drives consumers toward home-based solutions. Strong regional concentration is evident in North America and Asia Pacific, where consumer awareness, digital infrastructure, and cancer prevalence create favorable growth environments.

Report Coverage

The research report offers an in-depth analysis based on Cancer Type, Sample Type, Distribution Channel, and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The At-Home Cancer Testing market is expected to grow steadily with increasing consumer preference for convenient and non-invasive cancer screening solutions.
Advances in liquid biopsy and genetic testing technologies will significantly improve test accuracy and broaden cancer detection capabilities.
The direct-to-consumer model will become more dominant as companies focus on offering easy-to-use home testing kits with digital support.
Integration of telehealth services and mobile health applications will enhance user engagement and facilitate real-time consultation and result interpretation.
Online pharmacies and e-commerce platforms will continue to expand, offering wider access to at-home cancer testing kits globally.
North America will maintain a strong market presence due to high consumer awareness, while Asia Pacific will emerge as the fastest-growing region driven by healthcare advancements and rising cancer cases.
Companies will prioritize partnerships and collaborations to strengthen distribution networks and expand their global reach.
The blood sample segment will remain the preferred testing method due to its simplicity, accuracy, and wide application range.
Continuous efforts to improve affordability and accessibility will increase product penetration in developing regions.
Regulatory approvals and quality assurance will remain critical factors influencing new product launches and market entry.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: AT HOME CANCER TESTING MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Product

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Product & Distribution Channel Revenue

CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global At Home Cancer Testing Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global At Home Cancer Testing Export Revenue By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global At Home Cancer Testing: Company Market Share

7.2. Global At Home Cancer Testing Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: AT HOME CANCER TESTING MARKET – BY CANCER TYPE SEGMENT ANALYSIS

8.1. At Home Cancer Testing Overview by Cancer Type Segment

8.1.1. At Home Cancer Testing Revenue Share By Cancer Type

8.2. Colon

8.3. Breast

8.4. Prostate

8.5. Blood

8.6. Bladder

8.7. Others

CHAPTER NO. 9: AT HOME CANCER TESTING MARKET – BY SAMPLE TYPE SEGMENT ANALYSIS

9.1. At Home Cancer Testing Overview by Sample Type Segment

9.1.1. At Home Cancer Testing Revenue Share By Sample Type

9.2. Blood

9.3. Urine

9.4. Cell

9.5. Stool

9.6. Others

CHAPTER NO. 10: AT HOME CANCER TESTING MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS

10.1. At Home Cancer Testing Overview by Distribution Channel Segment

10.1.1. At Home Cancer Testing Revenue Share By Distribution Channel

10.2. Hospital Pharmacies

10.3. Retail Pharmacies

10.4. Online Pharmacies

10.5. Others

CHAPTER NO. 11: AT HOME CANCER TESTING MARKET – REGIONAL ANALYSIS

11.1. At Home Cancer Testing Overview by Region Segment

11.1.1. Global At Home Cancer Testing Revenue Share By Region

11.1.2. Regions

11.1.3. Global At Home Cancer Testing Revenue By Region

11.1.4. Cancer Type

11.1.5. Global At Home Cancer Testing Revenue By Cancer Type

11.1.6. Sample Type

11.1.7. Global At Home Cancer Testing Revenue By Sample Type

11.1.8. Distribution Channel

11.1.9. Global At Home Cancer Testing Revenue By Distribution Channel

CHAPTER NO. 12: NORTH AMERICA AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

12.1. North America At Home Cancer Testing Overview by Country Segment

12.1.1. North America At Home Cancer Testing Revenue Share By Region

12.2. North America

12.2.1. North America At Home Cancer Testing Revenue By Country

12.2.2. Cancer Type

12.2.3. North America At Home Cancer Testing Revenue By Cancer Type

12.2.4. Sample Type

12.2.5. North America At Home Cancer Testing Revenue By Sample Type

12.2.6. Distribution Channel

12.2.7. North America At Home Cancer Testing Revenue By Distribution Channel

2.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13: EUROPE AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

13.1. Europe At Home Cancer Testing Overview by Country Segment

13.1.1. Europe At Home Cancer Testing Revenue Share By Region

13.2. Europe

13.2.1. Europe At Home Cancer Testing Revenue By Country

13.2.2. Cancer Type

13.2.3. Europe At Home Cancer Testing Revenue By Cancer Type

13.2.4. Sample Type

13.2.5. Europe At Home Cancer Testing Revenue By Sample Type

13.2.6. Distribution Channel

13.2.7. Europe At Home Cancer Testing Revenue By Distribution Channel

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14: ASIA PACIFIC AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific At Home Cancer Testing Overview by Country Segment

14.1.1. Asia Pacific At Home Cancer Testing Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific At Home Cancer Testing Revenue By Country

14.2.2. Cancer Type

14.2.3. Asia Pacific At Home Cancer Testing Revenue By Cancer Type

14.2.4. Sample Type

14.2.5. Asia Pacific At Home Cancer Testing Revenue By Sample Type

14.2.5. Distribution Channel

14.2.7. Asia Pacific At Home Cancer Testing Revenue By Distribution Channel

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15: LATIN AMERICA AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

15.1. Latin America At Home Cancer Testing Overview by Country Segment

15.1.1. Latin America At Home Cancer Testing Revenue Share By Region

15.2. Latin America

15.2.1. Latin America At Home Cancer Testing Revenue By Country

15.2.2. Cancer Type

15.2.3. Latin America At Home Cancer Testing Revenue By Cancer Type

15.2.4. Sample Type

15.2.5. Latin America At Home Cancer Testing Revenue By Sample Type

15.2.6. Distribution Channel

15.2.7. Latin America At Home Cancer Testing Revenue By Distribution Channel

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16: MIDDLE EAST AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

16.1. Middle East At Home Cancer Testing Overview by Country Segment

16.1.1. Middle East At Home Cancer Testing Revenue Share By Region

16.2. Middle East

16.2.1. Middle East At Home Cancer Testing Revenue By Country

16.2.2. Cancer Type

16.2.3. Middle East At Home Cancer Testing Revenue By Cancer Type

16.2.4. Sample Type

16.2.5. Middle East At Home Cancer Testing Revenue By Sample Type

16.2.6. Distribution Channel

16.2.7. Middle East At Home Cancer Testing Revenue By Distribution Channel

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17: AFRICA AT HOME CANCER TESTING MARKET – COUNTRY ANALYSIS

17.1. Africa At Home Cancer Testing Overview by Country Segment

17.1.1. Africa At Home Cancer Testing Revenue Share By Region

17.2. Africa

17.2.1. Africa At Home Cancer Testing Revenue By Country

17.2.2. Cancer Type

17.2.3. Africa At Home Cancer Testing Revenue By Cancer Type

17.2.4. Sample Type

17.2.5. Africa At Home Cancer Testing Revenue By Sample Type

17.2.6. Distribution Channel

17.2.7. Africa At Home Cancer Testing Revenue By Distribution Channel

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18: COMPANY PROFILES

18.1. Exact Sciences Corporation

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Guardant Health

18.3. Grail, Inc.

18.4. Everlywell

18.5. Natera

18.6. Illumina Inc.

18.7. Cisco

18.8. Myriad Genetics Inc.

18.9. NeoGenomics Laboratories

18.10. Freenome Holdings Inc.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Frequently Asked Questions

What is the current size of the At-Home Cancer Testing Market?

The At-Home Cancer Testing Market is valued at USD 8,047.53 million in 2024 and is projected to reach USD 11,576.07 million by 2032.

What are the key segments within the At-Home Cancer Testing Market?

The market is segmented by cancer type, sample type, and distribution channel, with blood samples and online pharmacies holding the largest shares.

What are some challenges faced by the At-Home Cancer Testing Market?

Key challenges include regulatory hurdles, risk of misinterpretation, and limited awareness in developing regions.

Who are the major players in the At-Home Cancer Testing Market?

Major players include Exact Sciences Corporation, Guardant Health, Grail, Inc., Everlywell, Natera, Illumina Inc., and Myriad Genetics Inc.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –